KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBT Margin (2016 - 2025)

Historic EBT Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 22.32%.

  • Halozyme Therapeutics' EBT Margin fell 821200.0% to 22.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.43%, marking a year-over-year decrease of 214400.0%. This contributed to the annual value of 33.43% for FY2025, which is 214400.0% down from last year.
  • Per Halozyme Therapeutics' latest filing, its EBT Margin stood at 22.32% for Q4 2025, which was down 821200.0% from 61.81% recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' EBT Margin ranged from a high of 67.07% in Q2 2021 and a low of 22.32% during Q4 2025
  • Over the past 5 years, Halozyme Therapeutics' median EBT Margin value was 49.96% (recorded in 2024), while the average stood at 45.63%.
  • In the last 5 years, Halozyme Therapeutics' EBT Margin surged by 555800bps in 2021 and then crashed by -821200bps in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' EBT Margin stood at 53.73% in 2021, then dropped by -27bps to 39.0% in 2022, then rose by 13bps to 43.98% in 2023, then soared by 36bps to 59.8% in 2024, then crashed by -137bps to 22.32% in 2025.
  • Its EBT Margin was 22.32% in Q4 2025, compared to 61.81% in Q3 2025 and 62.92% in Q2 2025.